Evoke Pharma

EVOK

Market cap $8.06M

Overview Fund Activity

5.17 USD

-0.01

0.19%

At close Updated Sep 12, 4:00 PM EDT

1 day

-0.19%

5 days

1.57%

1 month

3.61%

3 months

75.25%

6 months

40.49%

Year to date

15.66%

1 year

23.39%

5 years

-99.29%

10 years

-98.93%

About: Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

Employees: 3

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

11% more funds holding

Funds holding: 9 [Q1] → 10 (+1) [Q2]

0.71% less ownership

Funds ownership: 16.26% [Q1] → 15.54% (-0.71%) [Q2]

9% less capital invested

Capital invested by funds: $666K [Q1] → $604K (-$62.4K) [Q2]

See Fund Rankings

Financial journalist opinion

Based on 3 articles about EVOK published over the past 30 days

MAI Capital Management Announces Strategic Partnership with Evoke Advisors

CLEVELAND & LOS ANGELES--(BUSINESS WIRE)--MAI Capital Management strategically partners with Evoke Advisors. Together, the firm will manage approximately $60 billion across over 30 offices.

MAI Capital Management Announces Strategic Partnership with Evoke Advisors

Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship

Separately Secures Access to OneGI Through Brentwood Pharmacy Agreement Gimoti Specialty Pharmacy Network to Almost Double with Additional Relationships SOLANA BEACH, Calif. and CHICAGO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on developing treatments for gastrointestinal (GI) diseases, with a particular emphasis on GIMOTI® (metoclopramide) nasal spray, together with EVERSANA, a leading provider of global commercial services to the life sciences industry, today announced the addition of Omnicell (NASDAQ: OMCL), a leader in medication management and fulfillment.

Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship

Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book

SOLANA BEACH, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that U.S. Patent No. 12,377,064 covering the use of GIMOTI® (metoclopramide) nasal spray in patients with moderate to severe symptoms of gastroparesis, has been listed in the U.S. Food and Drug Administration's (FDA) Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the “Orange Book”.

Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book

Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038

Extends market exclusivity for GIMOTI® to November 2038, nearly two additional years beyond original 2036 projection Extends market exclusivity for GIMOTI® to November 2038, nearly two additional years beyond original 2036 projection

Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038

Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036

SOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application covering the use of GIMOTI® in patients with moderate to severe symptoms of gastroparesis.

Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036

Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update

Q1 2025 Net Product Sales Increased 77% Year-over-Year to $3.1 Million Sustained Momentum Driven by Growing Prescriber Adoption and Repeat Patient Use SOLANA BEACH, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.

Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update

Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025

SOLANA BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders with an emphasis on GIMOTI®, today announced that a new abstract comparing the incidence of tardive dyskinesia (TD) in patients receiving continuous versus intermittent oral metoclopramide (OMCP) treatment has been accepted for presentation at Digestive Disease Week® (DDW) 2025, taking place May 3–6, 2025, in San Diego, CA.

Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025

Proactive Investors

evoke makes a steady exit from the Q1 starting gate

Evoke PLC (LSE:EVOK) has kicked off 2025 with a steady start, reporting first-quarter revenue of £437.00 million—up 1% on last year and pretty much bang on with what it had guided. So far this year, revenue is up around 4%, and the company says it's still aiming for full-year growth in the 5-9% range.

evoke makes a steady exit from the Q1 starting gate

Proactive Investors

William Hill owner Evoke falls at the first-quarter update

Evoke PLC (LSE:EVOK) shares plummeted 18% after the William Hill owner reported annual results in line with expectations but revealed slower growth at the start of 2025. Results for the past calendar year showed revenues up 3% to £1.75 billion and reported losses before tax more than tripling to £191.4 million from £65.2 million the previous year.

William Hill owner Evoke falls at the first-quarter update

Evoke Pharma, Inc. (EVOK) Q4 2024 Earnings Call Transcript

Evoke Pharma, Inc. (NASDAQ:EVOK ) Q4 2024 Earnings Conference Call March 13, 2025 4:30 PM ET Company Participants Daniel Kontoh-Boateng – DKB Partners Matt D'Onofrio – Chief Executive Officer Chris Quesenberry – Chief Commercial Officer, GIMOTI, EVERSANA Mark Kowieski – Chief Financial Officer Conference Call Participants Yale Jen – Laidlaw & Company Operator Good afternoon, and welcome to the Evoke Pharma Fourth Quarter and Full Year 2024 Earnings Conference Call. Currently all callers have been placed in a listen-only mode and following management's prepared remarks, the call will be opened for your questions.

Evoke Pharma, Inc. (EVOK) Q4 2024 Earnings Call Transcript

See News Rankings

Charts implemented using Lightweight Charts™